Hefei Tuorui Biotechnology

Hefei Tuorui Biotechnology is a clinical-stage biopharmaceutical company headquartered in Hefei, China, focusing on the development of next-generation small molecule targeted therapies for cancer. The company's research and development efforts are centered on overcoming resistance mechanisms and improving the therapeutic window of established oncology targets. Its lead program, TR001, is a potent and selective CDK4/6 inhibitor currently undergoing clinical evaluation for breast cancer and other solid tumors. Additionally, the company is advancing TR002, a PI3Kα inhibitor, alongside a pipeline of early-stage candidates targeting key oncogenic drivers. Tuorui Biotechnology aims to provide high-quality, affordable innovative medicines to patients worldwide through its integrated drug discovery platform.